Lineage Cell (Israel) Performance
| BTX Stock | ILS 217.00 5.00 2.36% |
The company secures a Beta (Market Risk) of -1.47, which conveys a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Lineage Cell are expected to decrease by larger amounts. On the other hand, during market turmoil, Lineage Cell is expected to outperform it. At this point, Lineage Cell Therapeutics has a negative expected return of -0.83%. Please make sure to verify Lineage Cell's accumulation distribution, and the relationship between the value at risk and day typical price , to decide if Lineage Cell Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Lineage Cell Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Total Cashflows From Investing Activities | 11.8 M |
Lineage |
Lineage Cell Relative Risk vs. Return Landscape
If you would invest 34,370 in Lineage Cell Therapeutics on September 13, 2024 and sell it today you would lose (12,670) from holding Lineage Cell Therapeutics or give up 36.86% of portfolio value over 90 days. Lineage Cell Therapeutics is producing return of less than zero assuming 5.9118% volatility of returns over the 90 days investment horizon. Simply put, 52% of all stocks have less volatile historical return distribution than Lineage Cell, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Lineage Cell Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lineage Cell's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Lineage Cell Therapeutics, and traders can use it to determine the average amount a Lineage Cell's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1408
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BTX |
Estimated Market Risk
| 5.91 actual daily | 52 52% of assets are less volatile |
Expected Return
| -0.83 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.14 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Lineage Cell is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lineage Cell by adding Lineage Cell to a well-diversified portfolio.
Lineage Cell Fundamentals Growth
Lineage Stock prices reflect investors' perceptions of the future prospects and financial health of Lineage Cell, and Lineage Cell fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lineage Stock performance.
| Price To Book | 1.14 X | |||
| Price To Sales | 39.20 X | |||
| Revenue | 4.99 M | |||
| EBITDA | (37.2 M) | |||
| Cash And Equivalents | 27.1 M | |||
| Cash Per Share | 0.18 X | |||
| Total Debt | 5.09 M | |||
| Debt To Equity | 3.10 % | |||
| Book Value Per Share | 1.09 X | |||
| Cash Flow From Operations | (30.88 M) | |||
| Total Asset | 101.66 M | |||
About Lineage Cell Performance
By analyzing Lineage Cell's fundamental ratios, stakeholders can gain valuable insights into Lineage Cell's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Lineage Cell has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Lineage Cell has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. BioTime, Inc. was founded in 1990 and is headquartered in Alameda, California. BIOTIME INC operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 76 people.Things to note about Lineage Cell Therapeutics performance evaluation
Checking the ongoing alerts about Lineage Cell for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Lineage Cell Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Lineage Cell generated a negative expected return over the last 90 days | |
| Lineage Cell has high historical volatility and very poor performance | |
| The company reported the revenue of 4.99 M. Net Loss for the year was (45.99 M) with profit before overhead, payroll, taxes, and interest of 4.69 M. | |
| Lineage Cell Therapeutics has accumulated about 27.1 M in cash with (30.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.18. |
- Analyzing Lineage Cell's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lineage Cell's stock is overvalued or undervalued compared to its peers.
- Examining Lineage Cell's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Lineage Cell's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lineage Cell's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Lineage Cell's stock. These opinions can provide insight into Lineage Cell's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Lineage Stock analysis
When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |